Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TherOx aims for $100m Nasdaq listing

This article was originally published in Clinica

Executive Summary

Oxygen therapy specialist TherOx is looking to raise around $100m by floating its shares on the Nasdaq Stock Exchange. The Irvine, California-based company is planning the IPO to fund the development of its TherOx SuperSaturated oxygen therapy system, which is designed to reduce the amount of dead heart muscle that can occur in heart attack patients. According to TherOx, it is “the first company to demonstrate a statistically and clinically significant therapy for reduction in infarct size since the introduction of stents approximately ten years ago”. The company claims the market for heart attack treatment is valued at around $350m. TherOx will list under the symbol “THER”.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel